A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

Recruiting

Phase 3

MM120A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

Sponsor:

Definium Therapeutics US, Inc.

Code:

NCT06809595

Conditions

Generalized Anxiety Disorder

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Placebo

MM120 (LSD D-Tartrate)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-02. This information was provided to ClinicalTrials.gov by Definium Therapeutics US, Inc. on 2026-02-13.